Skip to main content
Have a personal or library account? Click to login
Oral N-acetylcysteine Trial for RYR1-related Myopathies Cover

Oral N-acetylcysteine Trial for RYR1-related Myopathies

By:   
Open Access
|Dec 2022

Abstract

Investigators from NIH, Hyperion Biotechnology Inc., and Hospital for Sick Children studied the effect of oral N-acetylcysteine (NAC) on decreasing oxidative stress and increasing physical endurance in individuals with ryanodine receptor 1-related myopathies (RYR1-RM).
Language: English
Page range: 4 - 4
Submitted on: Dec 14, 2020
Accepted on: Dec 21, 2020
Published on: Dec 30, 2022
Published by: Pediatric Neurology Briefs Publishers
In partnership with: Paradigm Publishing Services

© 2022 Vamshi Rao, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.